Physician profile
Daniel Mark Williams
NPI 1083265078
$9,325.37
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $1,896 · 2023: $2,176 · 2024: $4,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $79.50 · Travel and Lodging: $23.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $79.50 |
| Travel and Lodging | $23.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,862.64 | 2021-2024 | |
| Celgene Corporation | $928.18 | 2021-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $749.84 | 2021-2024 | Austedo, Austedo Xr, Ajovy |
| Lundbeck LLC | $604.04 | 2021-2024 | Vyepti |
| Emd Serono, INC. | $520.02 | 2022-2024 | Mavenclad, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $273.19 | 2022-2024 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $196.69 | 2021 | |
| Sk Life Science, INC. | $188.59 | 2021-2023 | Xcopri |
| Novartis Pharmaceuticals Corporation | $139.44 | 2022-2024 | |
| Lilly USA, LLC | $130.44 | 2021-2023 | Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $129.89 | 2022 | |
| Biogen, INC. | $95.62 | 2021-2024 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $79.07 | 2023-2024 | |
| Allergan, INC. | $76.03 | 2021 | |
| Argenx US, INC. | $56.43 | 2023-2024 | Vyvgart |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50.19 | 2021-2024 | |
| Eisai INC. | $43.92 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $36.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.17 | 2024 | Eohilia |
| Amneal Pharmaceuticals LLC | $24.74 | 2023 | Rytary |
| Janssen Pharmaceuticals, INC | $24.18 | 2021 | |
| Genentech USA, INC. | $19.49 | 2023 | Enspryng, Ocrevus |
| Csl Behring | $18.20 | 2021 | |
| Amgen INC. | $17.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.48 | 2024 | Nuedexta |
| Livanova USA, INC. | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.